509 related articles for article (PubMed ID: 32693197)
21. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial.
Melloni C; Dunning A; Granger CB; Thomas L; Khouri MG; Garcia DA; Hylek EM; Hanna M; Wallentin L; Gersh BJ; Douglas PS; Alexander JH; Lopes RD
Am J Med; 2017 Dec; 130(12):1440-1448.e1. PubMed ID: 28739198
[TBL] [Abstract][Full Text] [Related]
23. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.
Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP
JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783
[TBL] [Abstract][Full Text] [Related]
24. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
25. Non-Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves: Is the Door Still Open?
Aimo A; Giugliano RP; De Caterina R
Circulation; 2018 Sep; 138(13):1356-1365. PubMed ID: 30354416
[TBL] [Abstract][Full Text] [Related]
26. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial.
Collet JP; Berti S; Cequier A; Van Belle E; Lefevre T; Leprince P; Neumann FJ; Vicaut E; Montalescot G
Am Heart J; 2018 Jun; 200():44-50. PubMed ID: 29898848
[TBL] [Abstract][Full Text] [Related]
27. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Marcy TR; Truong T; Rai A
Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
[TBL] [Abstract][Full Text] [Related]
29. The role of apixaban for venous and arterial thromboembolic disease.
Prom R; Spinler SA
Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
[TBL] [Abstract][Full Text] [Related]
31. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
32. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
34. On-X aortic valve replacement patients treated with low-dose warfarin and low-dose aspirin.
Oo AY; Loubani M; Gerdisch MW; Zacharias J; Tsang GM; Perchinsky MJ; Hagberg RC; Joseph M; Sathyamoorthy M
Eur J Cardiothorac Surg; 2024 May; 65(5):. PubMed ID: 38621698
[TBL] [Abstract][Full Text] [Related]
35. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
36. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin.
Vinereanu D; Lopes RD; Mulder H; Gersh BJ; Hanna M; de Barros E Silva PGM; Atar D; Wallentin L; Granger CB; Alexander JH;
Stroke; 2017 Dec; 48(12):3266-3273. PubMed ID: 29089455
[TBL] [Abstract][Full Text] [Related]
37. A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists.
Touma L; Filion KB; Atallah R; Eberg M; Eisenberg MJ
Am J Cardiol; 2015 Feb; 115(4):533-41. PubMed ID: 25547937
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
[TBL] [Abstract][Full Text] [Related]
39. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
